National Center for Global Health, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy.
Antimicrob Resist Infect Control. 2022 May 21;11(1):74. doi: 10.1186/s13756-022-01113-y.
Patients hospitalised for COVID-19 may present with or acquire bacterial or fungal infections that can affect the course of the disease. The aim of this study was to describe the microbiological characteristics of laboratory-confirmed infections in hospitalised patients with severe COVID-19.
We reviewed the hospital charts of a sample of patients deceased with COVID-19 from the Italian National COVID-19 Surveillance, who had laboratory-confirmed bacterial or fungal bloodstream infections (BSI) or lower respiratory tract infections (LRTI), evaluating the pathogens responsible for the infections and their antimicrobial susceptibility.
Among 157 patients with infections hospitalised from February 2020 to April 2021, 28 (17.8%) had co-infections (≤ 48 h from admission) and 138 (87.9%) had secondary infections (> 48 h). Most infections were bacterial; LRTI were more frequent than BSI. The most common co-infection was pneumococcal LRTI. In secondary infections, Enterococci were the most frequently recovered pathogens in BSI (21.7% of patients), followed by Enterobacterales, mainly K. pneumoniae, while LRTI were mostly associated with Gram-negative bacteria, firstly Enterobacterales (27.4% of patients, K. pneumoniae 15.3%), followed by A. baumannii (19.1%). Fungal infections, both BSI and LRTI, were mostly due to C. albicans. Antibiotic resistance rates were extremely high in Gram-negative bacteria, with almost all A. baumannii isolates resistant to carbapenems (95.5%), and K. pneumoniae and P. aeruginosa showing carbapenem resistance rates of 59.5% and 34.6%, respectively.
In hospitalised patients with severe COVID-19, secondary infections are considerably more common than co-infections, and are mostly due to Gram-negative bacterial pathogens showing a very high rate of antibiotic resistance.
因 COVID-19 住院的患者可能出现或感染可影响疾病进程的细菌或真菌感染。本研究旨在描述严重 COVID-19 住院患者实验室确诊感染的微生物学特征。
我们回顾了意大利国家 COVID-19 监测中死于 COVID-19 的患者样本的住院病历,这些患者的实验室确诊了细菌或真菌性血流感染(BSI)或下呼吸道感染(LRTI),评估了感染的病原体及其抗菌药物敏感性。
在 2020 年 2 月至 2021 年 4 月住院的 157 名感染患者中,28 名(17.8%)发生了合并感染(入院后 ≤ 48 小时),138 名(87.9%)发生了继发感染(入院后 > 48 小时)。大多数感染为细菌性;LRTI 比 BSI 更常见。最常见的合并感染是肺炎链球菌性 LRTI。在继发感染中,肠球菌是 BSI 中最常分离到的病原体(21.7%的患者),其次是肠杆菌科,主要是肺炎克雷伯菌,而 LRTI 主要与革兰氏阴性菌相关,首先是肠杆菌科(27.4%的患者,肺炎克雷伯菌 15.3%),其次是鲍曼不动杆菌(19.1%)。BSI 和 LRTI 的真菌感染主要是由白念珠菌引起的。革兰氏阴性菌的抗生素耐药率极高,几乎所有鲍曼不动杆菌分离株均对碳青霉烯类耐药(95.5%),肺炎克雷伯菌和铜绿假单胞菌的碳青霉烯类耐药率分别为 59.5%和 34.6%。
在严重 COVID-19 住院患者中,继发感染明显比合并感染更为常见,主要由革兰氏阴性细菌病原体引起,这些病原体对抗生素的耐药率非常高。